Cytokinetics to Announce Third Quarter Results on November 6, 2024
23 oct. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 6, 2024 at...
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
23 oct. 2024 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare...
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
23 oct. 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
23 oct. 2024 06h00 HE
|
Klotho Neurosciences, Inc.
Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
Smart Immune détermine la dose recommandée de SMART101 pour ses essais cliniques en oncologie
23 oct. 2024 01h01 HE
|
Smart Immune
La phase I d'escalade de dose de ReSET-02 chez des adultes souffrant de cancers hématologiques est terminée.Le segment randomisé de la phase II de cet essai est en cours.Aucune toxicité limitant la...
Smart Immune Announces Recommended SMART101 Dose for Adult Cancer Proof-of-Concept Trials
23 oct. 2024 01h01 HE
|
Smart Immune
ReSET-02 dose escalation Phase I is completedPhase II PoC randomized segment is starting No dose-limiting toxicities, no safety or tolerability issuesThe highest dose is to be used in both...
Keiretsu Forum’s Last Call for the 2024 Investor Capital Expo
22 oct. 2024 07h31 HE
|
Keiretsu Forum Mid-Atlantic
Investor Event to Feature Expert Panel on Early-Stage Investing and Presentation of the Stephen M. Goodman Most Valued Company Award
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
22 oct. 2024 07h02 HE
|
Ocugen
Determined the high dose of OCU410ST to be the maximum tolerated doseNo serious adverse events have been reportedApproved proceeding to Phase 2 using high and medium doses of OCU410ST MALVERN, Pa.,...
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
22 oct. 2024 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
Immunohistochemistry Market to Grow at USD 5.5 Billion by 2031 | SkyQuest Technology
21 oct. 2024 08h00 HE
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Immunohistochemistry Market size was valued at around USD 3.1 billion in 2023 to reach a value of USD 5.5 billion by 2031, at a CAGR of 7.4% over the...